Erratum: The association of statin use after cancer diagnosis with survival in pancreatic cancer patients: A Seer-Medicare analysis (PLoS ONE (2015) 10:4 (e0121783) DOI:doi:10.1371/journal.pone.0121783);The association of statin use after cancer diagnosis with survival in pancreatic cancer patients: A SEER-Medicare analysis

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Jeon, Christie Y ^a,b   Pandol, Stephen J ^a,c   Wu, Bechien ^d   Cook Wiens, Galen ^a   Gottlieb, Roberta A ^a   Merz, Noel Bairey ^a   Goodman, Marc T ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d KAISER PERMANENTE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; ANTINEOPLASTIC AGENT;

AGE DISTRIBUTION; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC PANCREATITIS; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DRUG MEGADOSE; DRUG POTENCY; DRUG USE; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HUMAN; INCOME; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OBESITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; RETROSPECTIVE STUDY; RISK REDUCTION; SURVIVAL TIME; TREATMENT DURATION; TUMOR VOLUME; VERY ELDERLY; CANCER REGISTRY; CARCINOMA, PANCREATIC DUCTAL; KAPLAN MEIER METHOD; MEDICARE; MORTALITY; MULTIVARIATE ANALYSIS; PANCREATIC NEOPLASMS; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME; UNITED STATES;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, PANCREATIC DUCTAL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KAPLAN-MEIER ESTIMATE; MALE; MEDICARE; MULTIVARIATE ANALYSIS; PANCREATIC NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SEER PROGRAM; TREATMENT OUTCOME; UNITED STATES;

EID: 84927546856     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0128730     Document Type: Erratum

References (23)

1. American Cancer Society. Cancer facts & figures 2013. Atlanta, GA: The Society; 2013. p. v.
2. Matrisian LM, Aizenberg R, Rosenzweig A. The Alarming Rise of Pancreatic Cancer Deaths in the United States: why we need to stem the tide today. Manhattan Beach, CA: Pancreatic Cancer Action Network, 2012.
3. th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2011. xlvii, 2638 p.677-8.
4. Gronich N, Rennert G. Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates. Nature reviews Clinical oncology. 2013 Nov; 10(11):625-42. PMID: 24080598. doi: 10.1038/nrclinonc. 2013.169
5. Nakai Y, Isayama H, Sasaki T, Mizuno S, Sasahira N, Kogure H, et al. Clinical outcomes of chemotherapy for diabetic and nondiabetic patients with pancreatic cancer: better prognosis with statin use in diabetic patients. Pancreas. 2013 Mar; 42(2):202-8. PMID: 23000889. doi: 10.1097/MPA. 0b013e31825de678
6. Hong JY, Nam EM, Lee J, Park JO, Lee SC, Song SY, et al. Randomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patients. Cancer chemotherapy and pharmacology. 2014 Jan; 73(1):125-30. PMID: 24162380. doi: 10.1007/s00280-013-2328-1
7. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Medical care. 2002 Aug; 40(8 Suppl):IV-3-18. PMID: 12187163.
8. Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Lloyd-Jones DM, Blum CB, et al. 2013 ACC/ AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology. 2013 Nov 7. PMID: 24239923.
9. Applied Research Program DoCCaPS, National Cancer Institute. Procedure Codes for SEER-Medicare Analyses Rockville, MD: National Cancer Institute; 2013 [cited 2014 March 31st]. Available: http://appliedresearch.cancer.gov/seermedicare/considerations/procedure-codes.html doi: 10.1002/ hed.23205 PMID: 23150453
10. Suissa S. Immortal time bias in pharmaco-epidemiology. American journal of epidemiology. 2008 Feb 15; 167(4):492-9. PMID: 18056625.
11. Mayo SC, Gilson MM, Herman JM, Cameron JL, Nathan H, Edil BH, et al. Management of patients with pancreatic adenocarcinoma: national trends in patient selection, operative management, and use of adjuvant therapy. J Am Coll Surg. 2012 Jan; 214(1):33-45. PMID: 22055585. Pubmed Central PMCID: 3578342. doi: 10.1016/j.jamcollsurg.2011.09.022
12. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008 Sep 26; 321 (5897):1801-6. PMID: 18772397. Pubmed Central PMCID: 2848990. doi: 10.1126/science.1164368
13. Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nature medicine. 2011 Apr; 17(4):500-3. PMID: 21460848. Pubmed Central PMCID: 3755490. doi: 10.1038/nm.2344
14. Kushner JA. The role of aging upon beta cell turnover. The Journal of clinical investigation. 2013 Mar 1; 123(3):990-5. PMID: 23454762. Pubmed Central PMCID: 3582123. doi: 10.1172/JCI64095
15. Deramaudt T, Rustgi AK. Mutant KRAS in the initiation of pancreatic cancer. Biochimica et biophysica acta. 2005 Nov 25; 1756(2):97-101. PMID: 16169155.
16. Kusama T, Mukai M, Iwasaki T, Tatsuta M, Matsumoto Y, Akedo H, et al. 3-hydroxy-3-methylglutarylcoenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology. 2002 Feb; 122(2):308-17. PMID: 11832446.
17. Zhang J, Yang Z, Xie L, Xu L, Xu D, Liu X. Statins, autophagy and cancer metastasis. The international journal of biochemistry & cell biology. 2013 Mar; 45(3):745-52. PMID: 23147595.
18. Araki M, Maeda M, Motojima K. Hydrophobic statins induce autophagy and cell death in human rhabdomyosarcoma cells by depleting geranylgeranyl diphosphate. European journal of pharmacology. 2012 Jan 15; 674(2-3):95-103. PMID: 22094060.
19. Hashimoto D, Blauer M, Hirota M, Ikonen NH, Sand J, Laukkarinen J. Autophagy is needed for the growth of pancreatic adenocarcinoma and has a cytoprotective effect against anticancer drugs. European journal of cancer. 2014 May; 50(7):1382-90. PMID: 24503026. doi: 10.1016/j.ejca.2014.01.011
20. Ko YH, Cho YS, Won HS, Jeon EK, An HJ, Hong SU, et al. Prognostic significance of autophagy-related protein expression in resected pancreatic ductal adenocarcinoma. Pancreas. 2013 Jul; 42(5):829-35. PMID: 23429496. doi: 10.1097/MPA.0b013e318279d0dc
21. Rosenfeldt MT, O'Prey J, Morton JP, Nixon C, MacKay G, Mrowinska A, et al. p53 status determines the role of autophagy in pancreatic tumour development. Nature. 2013 Dec 12; 504(7479):296-300. PMID: 24305049. doi: 10.1038/nature12865
22. Bolego C, Baetta R, Bellosta S, Corsini A, Paoletti R. Safety considerations for statins. Current opinion in lipidology. 2002 Dec; 13(6):637-44. PMID: 12441888.
23. Franks P, Tancredi D, Winters P, Fiscella K. Cholesterol treatment with statins: who is left out and who makes it to goal? BMC health services research. 2010; 10:68. PMID: 20236527. Pubmed Central PMCID: 2846927. doi: 10.1186/1472-6963-10-68